NovoEight

RSS

turoctocog alfa

Authorised
This medicine is authorised for use in the European Union.

Overview

NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII. 

The medicine contains the active substance turoctocog alfa

This EPAR was last updated on 19/05/2021

Authorisation details

Product details
Name
NovoEight
Agency product number
EMEA/H/C/002719
Active substance
turoctocog alfa
International non-proprietary name (INN) or common name
turoctocog alfa
Therapeutic area (MeSH)
Hemophilia A
Anatomical therapeutic chemical (ATC) code
B02BD02
Publication details
Marketing-authorisation holder
Novo Nordisk A/S
Revision
13
Date of issue of marketing authorisation valid throughout the European Union
13/11/2013
Contact address

Novo Alle
Bagsværd - 2880
Denmark

Product information

01/10/2020 NovoEight - EMEA/H/C/002719 - II/0035

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

coagulation factor VIII

Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Novoeight can be used for all age groups.

Assessment history

Related content

How useful was this page?

Add your rating
Average
2 ratings
2 ratings